[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-512711-105":59,"doc-detail-512711-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","adverse-drug-reaction-news-sep-2024-vol26-no2","Adverse Drug Reaction News - Sep 2024 - Vol.26 - No.2","","A bulletin summarizes Health Sciences Authority (HSA) pediatric adverse event (AE) data from 2019 to 2023, including the number of valid reports, the most suspected pharmacotherapeutic groups, and the distribution of reported AE types. It highlights that most reports were assessed as non-serious and adds a scan of adulterated products detected by HSA from Nov 2022 to Dec 2023, including common adulterants. Case studies present suspected drug-related injury questions and guidance for healthcare professionals on safe use, reporting, and education points.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/adverse-drug-reaction-news-sep-2024-vol26-no2/512711/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/adverse-drug-reaction-news-sep-2024-vol26-no2/512711.png","ImageObject",300,407,{"name":92,"@type":93},"pop out","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-10-06",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What did HSA report about valid pediatric adverse event reports from 2019 to 2023?","Question",{"text":112,"@type":113},"HSA received 4,853 valid adverse event reports in the pediatric population (aged 17 years and below). The top suspected pharmacotherapeutic groups included antibiotics, NSAIDs, analgesics, cough preparations, and antihistamines.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which AE types were most commonly reported, and how were seriousness assessments described?",{"text":117,"@type":113},"More than half of reported AEs were skin reactions, followed by immune-mediated reactions and other systemic or respiratory disorders. Most reports were assessed as non-serious.",{"name":119,"@type":110,"acceptedAnswer":120},"What adulterated product categories and adulterants were most common from November 2022 to December 2023?",{"text":121,"@type":113},"The most common adulterated product category was for pain or inflammatory conditions, followed by weight loss products. Steroids were most common for pain/inflammatory products, while sibutramine was most common in weight loss products.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},512711,1791389010,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":4},962090760408,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Health Product Safety Information Summary Scan / click the QR code to  \nread the full issue online  \n􀂙 From 2019 to 2023, HSA received 4,853 valid adverse event (AE) reports in the paediatric population (aged 17 years and below) .  \n􀂙 The top five pharmacotherapeutic groups suspected of causing the AEs were antibiotics, non-steroidal antiinflammatory drugs (NSAIDs), analgesics, cough preparations and antihistamines.  \n􀂙 More than half of the AEs reported were skin reactions, followed by immune-mediated reactions, reactions affecting the body as a whole and respiratory disorders. Most of these reports were assessed as non-serious.  \nSummary of adulterated products reported to HSA from November 2022 to December 2023  \nPg 5-6  \n􀂙 The most common category of adulterated products detected by HSA in the period between November 2022 and December 2023 was those marketed for pain or inflammatory conditions, followed by weight loss products.  \n􀂙 Steroids were the most common adulterants found in products for pain or inflammatory conditions, while sibutramine was the most common in weight loss products.  \n􀂙 Healthcare professionals play an important role in detecting the use of illegal products through careful taking of their patient’s medication history (including complementary health products and supplements) and being vigilant for potential AEs, and reporting them to HSA.  \nAE Case in Focus: Test Yourself Pg 6-7  \nThis is a case of a 63-year-old man who presented with two weeks’ history of yellowing of the skin, tea-coloured urine and a recent onset of pruritus. These symptoms were preceded by a month of lethargy. On examination, he was found to be jaundiced with excoriation marks over both his upper limbs. His past medical history included type II diabetes mellitus, hyperlipidaemia and hypertension. He was on long term medication for his chronic conditions, which included vildagliptin/metformin 50mg/850mg (Galvus Met®) . He was previously on linagliptin, but was switched to Galvus Met® about a year ago in view of his suboptimal diabetic control. The initial investigations revealed a cholestatic pattern of deranged liver enzymes, with alkaline phosphatase at 208 U/L, alanine transaminase at 70 U/L, aspartate transaminase at 56 U/L, and bilirubin at 689 μmol/L. Prothrombin time was prolonged at 12.7 seconds. He also had acute kidney injury with a creatinine level of 486 μmol/L and urea of 27.2 mmol/L. His presentation and initial investigations revealed possible acute liver and kidney injuries. A transjugular liver biopsy procedure was performed, and the histology of the liver specimen showed evidence of cholestatic hepatitis with prominent canalicular cholestasis and bile plugs, accompanied by prominent lobular inflammation.  \nWhat could have contributed to the patient’s liver injury?  \nPublished by the Health Products Regulation Group, HSA and the HSA Product Vigilance Advisory Committee  \nAnalysis of adverse event reports in paediatrics from 2019 to 2023  \nPg 3-4  \n2 Adverse Drug Reaction News • Sep 2024 • Vol.26 • No.2   \nAE Case in Focus: Test Yourself Pg 4  \nThis is a case of a 50-year-old female with a history of poorly controlled eosinophilic asthma and was started on mepolizumab. However, her asthma remained poorly controlled and she was switched to subcutaneous dupilumab. She presented atthe asthma clinic in her third month of dupilumab initiation with palpitations, heat intolerance, loss of appetite and hand tremors. Her last (4th) dose of dupilumab was given four weeks prior to her presentation at the clinic. On examination, she hada diffusely enlarged thyroid with a bruit. Laboratory tests showed she had primary hyperthyroidism with elevated thyrotropin receptor antibody (TRAb) levels. Her thyroid ultrasound scan revealed a heterogenous thyroid gland with increased gland vascularity consistent with Graves’ Disease.  \nWhat could have caused Graves’ Disease in this patient?  \nNew patient factsheet on the safe use of allopuri","cbCaioEGgXjeHnBF","https://ap.wps.com/l/cbCaioEGgXjeHnBF","pdf",2028325,"English","# Key Points\n## Analysis of adverse event reports in paediatrics from 2019 to 2023\n## Summary of adulterated products (Nov 2022 to Dec 2023)\n## AE Case in Focus: Test Yourself\n### Possible contributor to liver injury\n### What could have caused Graves’ Disease\n## New patient factsheet on the safe use of allopurinol\n## Dear Healthcare Professional Letters on safety concerns\n## How to report suspected AEs to HSA?","[{\"question\":\"What did HSA report about valid pediatric adverse event reports from 2019 to 2023?\",\"answer\":\"HSA received 4,853 valid adverse event reports in the pediatric population (aged 17 years and below). The top suspected pharmacotherapeutic groups included antibiotics, NSAIDs, analgesics, cough preparations, and antihistamines.\"},{\"question\":\"Which AE types were most commonly reported, and how were seriousness assessments described?\",\"answer\":\"More than half of reported AEs were skin reactions, followed by immune-mediated reactions and other systemic or respiratory disorders. Most reports were assessed as non-serious.\"},{\"question\":\"What adulterated product categories and adulterants were most common from November 2022 to December 2023?\",\"answer\":\"The most common adulterated product category was for pain or inflammatory conditions, followed by weight loss products. Steroids were most common for pain/inflammatory products, while sibutramine was most common in weight loss products.\"}]","Adverse Drug Reaction News - Sep 2024 - Vol.26 - No.2 | PDF",1791274735]